These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 20370925)

  • 1. The Dutch consumer quality index: an example of stakeholder involvement in indicator development.
    Delnoij DM; Rademakers JJ; Groenewegen PP
    BMC Health Serv Res; 2010 Apr; 10():88. PubMed ID: 20370925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measuring Healthcare Providers' Performances Within Managed Competition Using Multidimensional Quality and Cost Indicators.
    Portrait FR; van der Galiën O; Van den Berg B
    Health Econ; 2016 Apr; 25(4):408-23. PubMed ID: 25702821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Netherlands: health system review.
    Schäfer W; Kroneman M; Boerma W; van den Berg M; Westert G; Devillé W; van Ginneken E
    Health Syst Transit; 2010; 12(1):v-xxvii, 1-228. PubMed ID: 21132996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cooperation amongst insurers on enhancing quality of care: precondition or substitute for competition?
    Stolper KCF; Boonen LHHM; Schut FT; Varkevisser M
    Health Econ Policy Law; 2021 Jul; 16(3):273-289. PubMed ID: 32690116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the reform of the Dutch healthcare into managed competition: Results of a Delphi study among experts.
    de Vries H; Vahl J; Muris J; Evers S; van der Horst H; Cheung KL
    Health Policy; 2021 Jan; 125(1):27-33. PubMed ID: 33189409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managed competition in the Netherlands-a qualitative study.
    Heinemann S; Leiber S; Gress S
    Health Policy; 2013 Feb; 109(2):113-21. PubMed ID: 23031431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing a national performance indicator framework for the Dutch health system.
    ten Asbroek AH; Arah OA; Geelhoed J; Custers T; Delnoij DM; Klazinga NS
    Int J Qual Health Care; 2004 Apr; 16 Suppl 1():i65-71. PubMed ID: 15059989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The patient experience of patient-centered communication with nurses in the hospital setting: a qualitative systematic review protocol.
    Newell S; Jordan Z
    JBI Database System Rev Implement Rep; 2015 Jan; 13(1):76-87. PubMed ID: 26447009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Competition policy for health care provision in the Netherlands.
    Schut FT; Varkevisser M
    Health Policy; 2017 Feb; 121(2):126-133. PubMed ID: 27923494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-stakeholder perspectives in defining health services quality indicators and dimensions: a concept mapping based comparison for cataract care between Singapore and The Netherlands.
    Stolk-Vos A; De Korne D; Lamoureux E; Wai C; Busschbach JJ; van de Klundert JJ
    BMJ Open; 2021 Apr; 11(4):e046226. PubMed ID: 33827846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stuck in the middle?: A perspective on ongoing pro-competitive reforms in Dutch mental health care.
    Westra D; Wilbers G; Angeli F
    Health Policy; 2016 Apr; 120(4):345-9. PubMed ID: 26994866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ranking sources of hospital quality information for orthopedic surgery patients: consequences for the system of managed competition.
    Bes RE; van den Berg B
    Patient; 2013; 6(2):75-80. PubMed ID: 23549928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stronger, but not (yet) an equal. The use of quality improvement instruments and strategies by patient organisations in the Netherlands.
    Peeters MG; Delnoij DM; Friele RD
    Soc Sci Med; 2014 Aug; 115():56-63. PubMed ID: 24949981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficiency versus quality in the NHS, in Portugal: methodologies for evaluation].
    Giraldes Mdo R
    Acta Med Port; 2008; 21(5):397-410. PubMed ID: 19187682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Governing healthcare through performance measurement in Massachusetts and the Netherlands.
    Van der Wees PJ; Nijhuis-van der Sanden MW; van Ginneken E; Ayanian JZ; Schneider EC; Westert GP
    Health Policy; 2014 May; 116(1):18-26. PubMed ID: 24138729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managed competition in the Netherlands: Do insurers have incentives to steer on quality?
    Stolper KCF; Boonen LHHM; Schut FT; Varkevisser M
    Health Policy; 2019 Mar; 123(3):293-299. PubMed ID: 30268584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-stakeholder perspectives in defining health-services quality in cataract care.
    Stolk-Vos AC; van de Klundert JJ; Maijers N; Zijlmans BLM; Busschbach JJV
    Int J Qual Health Care; 2017 Aug; 29(4):470-476. PubMed ID: 28498929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Strangers in the ER": Quality indicators and third party interference in Dutch emergency care.
    Moes FB; Houwaart ES; Delnoij DMJ; Horstman K
    J Eval Clin Pract; 2019 Jun; 25(3):390-397. PubMed ID: 29508476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.